The cell-free protein synthesis (CFPS) market is set to reach USD 308.9 million by 2030, growing at a CAGR of 7.3%. Key ...

New data from a phase 1b/2 clinical trial shows that a specific protein called CD47 can help predict how well the investigational drug evorpacept works for patients with metastatic breast cancer, ALX ...

The proteomics market is experiencing strong growth as demand rises for advanced tools that analyze protein structure, ...

Membrane proteins are vital for cellular signaling, transport, and communication, making them attractive drug targets despite their challenging properties. Advances in mass spectrometry have enabled ...

Bio-Techne Corporation (NASDAQ:TECH) Q2 2026 Earnings Call Transcript February 4, 2026 Bio-Techne Corporation beats earnings ...

Learn more about whether Tempus AI, Inc. or 10x Genomics, Inc. is a better investment based on AAII's A+ Investor grades, ...

Scientists discovered why some neurons resist tau toxicity, identifying CRL5SOCS4 as a crucial defense and linking ...

CD47 expression levels may predict evorpacept efficacy in HER2-positive metastatic breast cancer, especially in heavily pretreated patients. Evorpacept combined with zanidatamab shows promising ...

New research by UCLA Health and UC San Francisco has uncovered why certain brain cells are more resilient than others to the ...

Increase in demand for generic medicines have also led to increase in shift toward use of biotech ingredients. In addition, rise in consumption in the food & beverages industry and various health ...

A panel of four biomarkers had high accuracy for distinguishing cancer from noncancer ...

HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. A large-scale analysis reveals novel predictors of survival and resistance ...